Australia's COVID-19 Vaccine Cold Chain Challenges GRG















After nearly a year of lockdowns throughout Australia a return to normality is finally within sight. How well is Australia prepared for the logistical challenges of vaccine distribution?

Australian case numbers remain low by global standards, interstate travel is cautiously flowing, and two of the Australian Government’s vaccine partners, Pfizer, and AstraZeneca, have begun administering their vaccines throughout several countries including the United States, United Kingdom and India.

Australia appears to be in a good position to transition to what has regularly been referred to as ‘the new normal’ with vaccinations set to begin in late February.

Initial doses of the vaccines will be scarce, and preliminary distribution will be targeted at immunising those with greatest risk to the virus in Phase 1 of Australia’s 3 phase rollout.

Almost every aspect of Australia’s COVID-19 vaccine rollout will be a challenge, however Australia is set up for a successful rollout despite these challenges.

This article looks at how the vaccine will be distributed, and the challenges and opportunities unique to Australia's vaccine distribution including:

  • Onshore vaccine manufacturing
  • Digital vaccine supply chain
  • Lessons from recent pandemic responses
  • Experience in rapid supply chain deployment
  • Resilient nationwide cold chain

Download the article via the link below.

Download – PDF (1.9 MB)
Reproduction of GRA whitepapers and articles

GRA permit the reproduction of GRA authored whitepapers and articles so long as all the following conditions are understood and met:

  • Entire credit details must be included:
    • Author's name(s)
    • GRA name and contact details
    • GRA URL link to the original article
  • All hyperlinks within the article must also be retained
  • Articles must not be resold
  • GRA retain full copyright.

If you have any queries about reproducing a GRA article or whitepaper, please contact GRA Marketing